Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma

Journal of Clinical Oncology

Volumn 27, Issue 7, 2009, Pages 1041-1046

  Kushner, Brian H ^a   Kramer, Kim ^a   Modak, Shakeel ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CATECHOLAMINE;

ARTICLE; BONE MARROW; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CATECHOLAMINE URINE LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PATIENT MONITORING; PRIORITY JOURNAL; THERAPY EFFECT;

3-IODOBENZYLGUANIDINE; ADOLESCENT; BONE AND BONES; BONE MARROW; CATECHOLAMINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 61449184564     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6107     Document Type: Article

References (34)

1. Dubois SG, Kalika Y, Lukens JN, et al: Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181-189, 1999
2. Kushner BH: Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 45:1172-1188, 2004
3. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
4. Kushner BH, Yeh SDJ, Kramer K, et al: Impact of MIBG scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 21:1082-1086, 2003
5. Preacher KJ: Calculation for the chi-square test: An interactive calculation tool for chi-square tests of goodness of fit and independence. http://www.quantpsy.org
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
7. 123I- metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491, 2003
8. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 22:3909-3915, 2004
9. 123I- MIBG in patients with stage 4 neuroblastoma > 1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. Eur J Cancer 44:1552-1558, 2008
10. Maurea S, Lastoria S, Caraco C, et al: lodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: Comparison with laboratory analysis. J Nucl Med 35:1429-1435, 1994
11. Hadj-Djilani NL, Lebtahi NE, Delaloye AB, et al: Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 22:322-329, 1995
12. Kohnert K, Lerch H, Thelen M, et al: Follow-up of neuroblastoma stageIVby123-I-mIBG-scintigraphy, bone scintigraphy and catecholamine metabolites. Nuklearmedizin 35:220-224, 1996
13. Okuyama C, Ushijima Y, Kubota T, et al: Utility of follow-up studies using meta-[123 l]iodobenzyl-guanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun 23:663-672, 2002
14. Simon T, Hero B, Hunneman DH, et al: Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 39:1899-1903, 2003
15. Fox E, Maris JM, Widemann BC, et al: A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days in pediatric patients with solid tumors. Clin Cancer Res 12:4882-4887, 2006
16. Kushner BH, Kramer K, Modak S, et al: Irino-tecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24:5271-5276, 2006
17. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341:1165-1173, 1999
18. Gordon I, Peters AM, Gutman A, et al: Skeletal assessment in neuroblastoma: The pitfalls of iodine-123-MIBG scans. J Nucl Med 31:129-134, 1990
19. 99mTc-MDP scintigraphy. J Nucl Biol Med 37:107-114, 1993
20. Perel Y, Conway J, Kletzel M, et al: Clinical impact and prognostic value of metaiodobenzylgua-nidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 21:13-18, 1999
21. Biasotti S, Garavanta A, Villavecchia GP, et al: False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 35:153-155, 2000
22. Hero B, Hunneman DH, Gahr M, et al: Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 36:220-223, 2001
23. Shulkin BL, Hutchingson RJ, Castle VP, et al: Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743-750, 1996
24. 18F-fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19:3397-3405, 2001
25. Bonnin F, Lumbroso J, Tenenbaum F, et al: Refining interpretation of MIBG scans in children. J Nucl Med 35:803-810, 1994
26. Kramer K, Kushner BH, Heller G, et al: Neuroblastoma metastatic to the central nervous system: The Memorial Sloan-Kettering Cancer Center experience and a literature review. Cancer 91:1510-1519, 2001
27. Matthay KK, Brisse H, Couanet D, et al: Central nervous system metastases in neuroblastoma: Radiologic, clinical, and biologic features in 23 patients. Cancer 98:155-165, 2003
28. Brenner DJ, Hall EJ: Computed tomography: An increasing source of radiation exposure. N Engl J Med 357:2277-2284, 2007
29. 123l-metaiodobenzylguanidine (MIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30:BP132-BP139, 2003
30. Tubiana M, Arengo A, Averbeck D, et al: Low-dose risk assessment: Comments on the summary of the international workshop. Radiat Res 167:742-744, 2007
31. Cotterill SJ, Pearson ADJ, Pritchard J, et al: Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: A report from the European Neuroblastoma Study Group "Survey." Med Pediatr Oncol 36:235-238, 2001
32. Kushner BH, Kramer K, Cheung N-KV: Chronic neuroblastoma: Indolentstage 4diseasein children. Cancer 95:1366-1375, 2002
33. Lau L, Tai D, Weitzman S, et al: Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 26:227-232, 2004
34. Santana V, Furman WL, McGregor LM, et al:Disease control intervals in high-risk neuroblastoma. Cancer 1 12:2796-2801, 2008